profit from every €100 of sales.
€0€100
AtaiBeckley
We have no price for AtaiBeckley since 9 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
€6.30+1.61% today
+29.2% in 1 year
1-year low €2.881-year high €6.60
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What AtaiBeckley sold, what it kept, and what it did with the cash.
Sales went from €233,000 in 2022 to €4.09 million in 2025, with -€660 million of profit last year.
SalesProfit
AtaiBeckley vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| AtaiBeckley | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads AtaiBeckley's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 4 | |
| – | – | – | – | |
| -144 | -123 | -102 | -113 | |
| -134 | -36 | -145 | -658 | |
| -152 | -40 | -149 | -660 | |
| -0.98 | -0.25 | -0.93 | -2.91 | |
| – | – | – | – | |
| -61,987.1% | -39,180.3% | -33,170.8% | -2,772.0% | |
| -65,401.3% | -12,810.2% | -48,464.0% | -16,142.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 305 | 293 | 159 | 293 |
| Cash | 191 | 45 | 18 | 85 |
| Total debt | 15 | 19 | 25 | 2 |
| Total liabilities | 40 | 49 | 43 | 71 |
| 261 | 243 | 116 | 222 | |
| 156 | 159 | 160 | 227 | |
| -34.0% | -9.8% | -72.1% | -205.9% | |
| -58.4% | -16.6% | -128.4% | -297.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -104 | -84 | -82 | -103 | |
| 1 | 1 | 0 | 11 | |
| -105 | -85 | -83 | -114 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 7 | |
| 42 | 33 | 25 | 14 |
Valuation
- –
- –
- –
- 5.4×
- 587.6×
- –
- –
- -4.7%
- -27.5%
- –
Profitability
- –
- -2,772.0%
- -16,142.0%
- –
- -205.9%
- -80.5%
- –
- –
- –
- –
Growth
- +159.9%
- –
- –
- –
- +13.3%
Financial health
- -0.1×
- 0.01
- –
- -566.9×
- 11.74
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 3%of 870
Bottom 20%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/5Passes 0 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
40No pass
Philip Fisher
28No pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
35No pass
Terry Smith
27No pass
Questions about AtaiBeckley
Is AtaiBeckley a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AtaiBeckley AI analysis
What does AtaiBeckley do?
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. It is in Biotechnology, based in New York, NY, United States, with 99 employees.
Is AtaiBeckley stock halal?
Yes. AtaiBeckley passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has AtaiBeckley stock done over the past year?
Up 29.2% over the past twelve months, to €6.30. It traded between €2.88 and €6.60 and is 4.5% below its high.
Who are AtaiBeckley's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with AtaiBeckley's.
Prices: daily closes to Sep 9, 2026. Fundamentals: company reports via invest-like data.